Quick Takeaways
- BC Global Opportunities IX LP filed SCHEDULE 13G for BridgeBio Oncology Therapeutics, Inc. Common Stock (BBOT).
- Disclosed ownership: 5.5%.
- Date of event: 04 Sep 2025.
BC Global Opportunities IX LP - 04 Sep 2025 SCHEDULE 13G Report for BridgeBio Oncology Therapeutics, Inc. Common Stock (BBOT)
- Filing Manager
- BC Global Opportunities IX LP
- Reporting Manager
- BC Global Opportunities IX LP
- Symbol
- BBOT
- Shares outstanding
- 79,377,218 shares
- Disclosed Ownership
- 4,365,747 shares
- Ownership
- 5.5%
- Form type
- SCHEDULE 13G
- Filing time
- 03 Sep 2025, 15:05:41 UTC
- Date of event
- 04 Sep 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"BC Global Opportunities IX LP disclosed 5.5% ownership in BridgeBio Oncology Therapeutics, Inc. Common Stock (BBOT) on 04 Sep 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 03 Sep 2025, 15:05.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (4)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| BC Global Opportunities IX LP | 5.5% | 4,365,747 | 0 | 4,365,747 | Freeman Szeto | Operation Manager | |
| BC General Partner, LP | 5.5% | 4,365,747 | 0 | 4,365,747 | Freeman Szeto | Operation Manager | |
| BC Capital Management Limited | 5.5% | 4,365,747 | 0 | 4,365,747 | Freeman Szeto | Operation Manager | |
| Tan Kuangming | 5.5% | 4,365,747 | 0 | 4,365,747 | Tan Kuangming | Director |